OpenNeedle Ask your own

Question explored with the scientific record

Conversation so far

  1. 1 Lamictal
  2. 2 Lamictal and should you taper off it

Answered on this page ↓

Lamictal and should you taper off it

Oct 28, 2026 · 5 sources used · OpenNeedle synthesis
Tapering Lamictal is usually safe if done slowly, but the evidence on how to do it is thin, and the risk of relapse is real.

The records here don't contain a single study of tapering or withdrawal from lamotrigine. That's a gap in what I can see, not proof it's unstudied. What they do show is why stopping matters: lamotrigine's benefit is in preventing relapse, and that benefit disappears when the drug does. A 36-week placebo-controlled trial in Chinese bipolar I adults found lamotrigine 200 mg/day was not significantly better than placebo overall at delaying a mood episode [5], though in patients with moderate or severe symptoms at baseline it cut the risk of relapse roughly in half (about 25 in 100 on lamotrigine vs 48 in 100 on placebo needed intervention) [5]. In a small rapid-cycling comparison, 6 of 7 on lamotrigine had fewer than four episodes in a year versus 3 of 7 on lithium [2]. Stop the drug and you go back to your untreated baseline.

FindingLamotriginePlacebo
Needed intervention, all patients [5]38.5%46.6%
Needed intervention, moderate/severe baseline [5]25.3%48.1%

Two things to know before you taper. First, a case report describes hypomania appearing within days of starting low-dose lamotrigine and mood staying stable off it [1], which raises the question of whether stopping can also destabilize mood. That's one case, not proof. Second, the serious rash risk is tied to starting and escalating, not stopping [3][4], so tapering doesn't carry that hazard.

The honest answer on how to taper: no retrieved study tells you the schedule. General practice is a gradual reduction over weeks, slower if you've been on it long or are also on valproate, which raises lamotrigine levels [3]. Do it with a clinician who knows your history, and have a plan for early relapse signs.

My call: taper slowly rather than stop abruptly, and expect your relapse risk to return to what it was before the drug. Confidence: moderate on the relapse risk, low on the specific taper schedule, because the evidence for it isn't here.

Keep digging

Sources used 5

  1. Hypomania with Low-Dose Lamotrigine Suggests it Really is an Antidepressant Current Research in Psychology and Behavioral Science (CRPBS) (2024) other Mixed

    The authors present a case of hypomania developing shortly after the initiation of low-dose lamotrigine in a patient with bipolar I disorder, leading them to propose that lamotrigine may function more as an antidepressant than a traditional mood stabilizer.

    DOI: 10.54026/crpbs/10110
  2. An open longitudinal study of patients with bipolar rapid cycling treated with lithium or lamotrigine for mood stabilization Bipolar Disorders (2000) primary study Strong

    In an open year-long randomized comparison of 14 refractory bipolar I rapid cycling patients, lamotrigine-treated patients had fewer relapses and more often stopped rapid cycling than lithium-treated patients.

    DOI: 10.1034/j.1399-5618.2000.020408.x
  3. Lamotrigine-induced severe cutaneous adverse reaction in a patient with N-methyl-D-aspartate receptor autoimmune encephalitis International Journal of Basic & Clinical Pharmacology (2026) other Strong

    A 20-year-old woman with NMDA receptor antibody-positive autoimmune encephalitis developed a probable lamotrigine-induced severe cutaneous adverse reaction after dose escalation with valproate co-therapy, and the rash resolved completely after lamotrigine withdrawal and systemic…

    DOI: 10.18203/2319-2003.ijbcp20261971
  4. Overview of Lamotrigine and the New Antiepileptic Drugs: The Challenge Journal of Child Neurology (1997) narrative review Strong

    Lamotrigine is effective as monotherapy or adjunctive therapy for pediatric and adult epilepsy, but its use requires balancing efficacy against serious rash risks, especially in children and with valproate or rapid titration.

    DOI: 10.1177/0883073897012001111
  5. A randomised, double-blind, placebo-controlled study to evaluate the safety and efficacy of lamotrigine in the maintenance treatment of Chinese adult patients with bipolar I disorder International Journal of Bipolar Disorders (2022) primary study Strong

    Lamotrigine 200 mg/day was not superior to placebo in preventing mood episode relapse/recurrence in Chinese adults with bipolar I disorder, though post hoc analyses suggested benefit in those with moderate/severe baseline symptoms.

    DOI: 10.1186/s40345-022-00266-4

Your question next

What do you want to know?

No question is too uncomfortable for the evidence. Bring yours.

Ask your question →